Research Library

This issue brief argues that continued investments in global health and the study of emerging pathogens could yield better tools to fight infectious diseases like the Zika virus long before they become a problem in the developed world.

In addition to their therapeutic potential, cord blood banks raise ethical and regulatory questions, especially in emerging markets in the Arab world. In this article, the authors review cord blood banking in five countries in the region (Jordan, Saudi Arabia, Egypt, Qatar, and the United Arab Emirates) that were selected for their different CB banking policies and initiatives.

The international Human Microbiome Project trumpeted the coming of age of the field of metagenomics, the study of entire communities of microbes and their contributions to health and disease. In parallel, the field of metabolomics emerged as the systematic, nonbiased analysis of all low-molecular-weight small molecules, or metabolites, produced by a system in response to an environmental stimulus. These fields have enabled discoveries pertinent to a number of human conditions — namely, acute gastroenteritis, antibiotic-associated diarrhea, inflammatory bowel disease, irritable bowel syndrome, liver disease, undernutrition and obesity — and have begun to shed new light on multiple aspects of the neglected tropical diseases.

Stem cells from umbilical cord blood (CB) can be used to treat over 80 different diseases, including many types of leukemia, lymphoma and inherited immune system disorders. Extensive storage facilities in the United States and around the world collect, test and freeze CB for later use in medical procedures. However, the divide between two different banking models — public versus private — presents policy challenges. This policy report examines the difference between public and private cord blood banks and offers recommendations for US policymakers to improve cord blood banking and ensure high quality standards.

Biotechnology scientists must be aware of the broad patent landscape and push for new patent and licensing guidelines, according to a new paper from the Baker Institute.

An introduction to stem cells and their potential uses.

Kirstin Matthews, fellow in science and technology, answers questions regarding the biology, practical uses and ethical dilemmas surrounding stem cells.

A Civic Scientist Précis on Stephen Minger, Ph.D.